AU Patent

AU2022433642A1 — Compositions comprising a chemokine receptor pathway inhibitor

Assigned to Dimerix Bioscience Pty Ltd · Expires 2024-05-09 · 2y expired

What this patent protects

A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; iii. a binder in a concentration from 2 to 5…

USPTO Abstract

A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; iii. a binder in a concentration from 2 to 5 % w/w; iv. a disintegrant in a concentration from 2 to 8% w/w; and v. a lubricant in a concentration from 0.05 to 5% w/w; and methods of treatment with same.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022433642A1
Jurisdiction
AU
Classification
—
Expires
2024-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Dimerix Bioscience Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.